Australia and New Zealand might have largely eliminated COVID-19, but for the $19 billion ASX and NZX-listed group Fisher & Paykel Healthcare, the fight is far from over.

Since the outbreak of the pandemic this year, F&P has been scrambling to keep up with the demand from hospitals for its humidifiers, which have become vital to the treatment of the disease.